Abstract

The estimation and monitoring of SpO2 are crucial for assessing lung function and treating chronic pulmonary diseases. The COVID-19 pandemic has highlighted the importance of early detection of changes in SpO2, particularly in asymptomatic patients with clinical deterioration. However, conventional SpO2 measurement methods rely on contact-based sensing, presenting the risk of cross-contamination and complications in patients with impaired limb perfusion. Additionally, pulse oximeters may not be available in marginalized communities and undeveloped countries.